

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1.-72. (Canceled)

73. (Previously Presented) An isolated polypeptide comprising SEQ ID NO:392.

74. (Previously Presented) An isolated polypeptide comprising an amino acid sequence having at least 90% identity to SEQ ID NO:392, wherein said polypeptide is over expressed in ovarian cancer relative to normal ovarian tissue, and wherein said polypeptide is not SEQ ID NO:393.

75. (Previously Presented) An isolated polypeptide comprising amino acid residues 1-27 of SEQ ID NO:392, wherein said polypeptide is over expressed in ovarian cancer relative to normal ovarian tissue.

76. (Previously Presented) An isolated polypeptide comprising amino acid residues 1-27 of SEQ ID NO:392, or a sequence having at least 90% identity to said polypeptide, wherein said polypeptide is over expressed in ovarian cancer relative to normal ovarian tissue.

77. (Previously Presented) An isolated polypeptide comprising an amino acid sequence having at least 90% identity to amino acid residues 1-27 of SEQ ID NO:392, wherein said polypeptide is over expressed in ovarian cancer relative to normal ovarian tissue.

78. (Previously Presented) A fusion polypeptide comprising a polypeptide according to any one of claims 73-77.

79. (Previously Presented) A composition comprising a polypeptide according to any one of claims 73-77 and at least one physiologically acceptable excipient.

80. (Previously Presented) A composition comprising a polypeptide according to any one of claims 73-77 and at least one adjuvant.

81. (Previously Presented) The composition of claim 80, wherein the adjuvant is selected from the group consisting of: an MPL, QS21 and AS-2.